Chadwick Jeremy G 4
4 · Kymera Therapeutics, Inc. · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) COO Jeremy Chadwick Exercises Options & Sells Shares
What Happened
- Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics (KYMR), exercised stock options and sold shares in transactions on March 23 and March 25, 2026. He exercised a total of 109,127 shares (84,400 on 3/23 and 24,727 on 3/25) at an exercise price of $29.64, paying about $3.23 million in aggregate.
- Following the exercises, Chadwick disposed of multiple blocks of shares in the open market: a total of ~115,977 shares across several trades (major blocks on 3/23 and 3/25) for aggregate gross proceeds of about $9.05 million. The activity appears routine (exercises followed by sales), rather than an outright purchase.
Key Details
- Transaction dates and prices:
- 2026-03-23: Exercised 84,400 shares @ $29.64 (cost ≈ $2,501,616); sold multiple lots totaling 91,250 shares at weighted-average prices between ~$75.96–$80.00 (combined proceeds ≈ $7.06M).
- 2026-03-25: Exercised 24,727 shares @ $29.64 (cost ≈ $732,908); sold 24,727 shares @ $80.26 (proceeds ≈ $1.98M).
- Aggregate exercised = 109,127 shares (exercise cost ≈ $3.23M). Aggregate sold = ~115,977 shares (gross proceeds ≈ $9.05M).
- Shares owned after transaction: not provided in the excerpt you supplied.
- Footnotes / notable items:
- Transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 (F1).
- Several sales prices are reported as weighted averages covering price ranges (F2–F6). Vesting terms for the option grant are noted (25% vested May 22, 2024; remainder vest monthly over 36 months) (F7).
- Derivative entries showing $0 reflect conversion/exercise of options (standard reporting notation).
- Filing timeliness: Form filed March 25, 2026 for trades on March 23 and March 25 — not indicated as late in the provided data.
Context
- These transactions are classic option exercises followed by open-market sales. While exercises indicate the insider converted options into shares, the immediate sales mean this is not a fresh personal purchase that would signal increased insider ownership. The presence of a 10b5-1 plan suggests trades were preplanned and potentially automated.
Insider Transaction Report
Form 4
Chadwick Jeremy G
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-23$29.64/sh+84,400$2,501,616→ 152,452 total - Sale
Common Stock
[F1][F2]2026-03-23$76.73/sh−22,756$1,746,134→ 129,696 total - Sale
Common Stock
[F1][F3]2026-03-23$77.21/sh−52,975$4,089,983→ 76,721 total - Sale
Common Stock
[F1][F4]2026-03-23$78.40/sh−8,214$643,950→ 68,507 total - Sale
Common Stock
[F1][F5]2026-03-23$79.87/sh−6,105$487,609→ 62,402 total - Sale
Common Stock
[F1]2026-03-23$80.05/sh−1,200$96,060→ 61,202 total - Exercise/Conversion
Common Stock
[F1]2026-03-25$29.64/sh+24,727$732,908→ 85,929 total - Sale
Common Stock
[F1][F6]2026-03-25$80.26/sh−24,727$1,984,554→ 61,202 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-03-23−84,400→ 115,600 totalExercise: $29.64Exp: 2033-05-22→ Common Stock (84,400 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-03-25−24,727→ 90,873 totalExercise: $29.64Exp: 2033-05-22→ Common Stock (24,727 underlying)
Footnotes (7)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $76,94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.95 to $77.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.98 to $78.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.01 to $80.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact|2026-03-25